Ocular Therapeutix, Inc. OCUL R2K
Healthcare · Biotechnology · United States
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
READ MORE ›$9.01
+12.48% 1Y
Market & Price
Market Cap
$1.97B
Current Price
$9.01
High / Low (52W)
$16.11 / $6.88
Beta
0.93
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$3.03
Price to Book
2.97
P/S
37.91
EV/EBITDA
-4.70
Dividend Yield
-
Profitability & Returns
ROCE
-33.56%
ROE
-68.55%
ROA
-32.88%
Profit Margin
0.00%
Op Margin
-
EPS (Latest Qtr)
$-0.40
EPS (TTM)
$-1.44
Balance Sheet & Liquidity
Debt/Equity
0.14
Quick Ratio
14.49
Current Ratio
14.81
Debt
$79.46M
Total Assets
$808.06M
Current Assets
$782.13M
Working Capital
$731.32M
Ownership
Promoter Holding
0.87%
Chg in Prom Hold
-0.00%
FII / Inst Holding
95.67%
Chg in FII Hold
0.00%
Financial Snapshot
Enterprise Value
$1.39B
Total Revenue (TTM)
$52.04M
EBITDA
$-294.82M
Free Cash Flow
$-148.76M
Operating Cash Flow
$-226.20M
Shares Outstanding
218.96M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
0.29%
Profit 5Y
-91.45%
Revenue (YoY)
0.80%
Earnings (YoY)
-
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -91.5% CAGR over 5 years.
- Trading 44.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OCUL Ocular Therapeutix, Inc. R2K | 9.01 | - | $1.97B | - | -33.56% | -68.55% | 0.29% | -91.45% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 340.00K | 648.00K | 498.00K | 504.00K | 492.00K | 650.00K | 829.00K | 2.26M | 2.61M | 1.57M | 5.88M | 7.34M | 11.72M | 12.15M | 13.19M | 12.27M | 11.96M | 13.37M | 15.19M | 15.08M | 14.77M | 16.44M | 15.43M | - | 10.70M | 13.46M | 14.54M | 13.25M | 10.79M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.26M | 1.94M | 1.77M | 1.59M | 1.33M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.44M | 11.52M | 12.77M | 11.66M | 9.46M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 73.35M | 79.16M | 81.47M | 81.42M | 102.80M |
| Operating Income | -9.63M | -11.17M | -10.28M | -10.51M | -11.11M | -9.24M | -12.47M | -15.67M | -18.34M | -15.20M | -12.72M | -13.46M | -13.56M | -14.82M | -17.28M | -19.66M | -21.60M | -23.14M | -21.40M | -16.61M | -17.88M | -14.01M | -20.23M | -20.23M | -19.53M | -17.83M | -19.92M | -21.54M | -22.55M | -20.57M | -19.21M | -31.62M | -43.59M | -46.00M | - | -63.92M | -67.64M | -68.70M | -69.76M | -93.34M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -60.09M | -63.77M | -65.35M | -60.58M | -84.55M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.98M | 3.02M | 3.00M | 2.83M | 2.78M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -64.05M | -67.81M | -69.42M | -64.65M | -88.61M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -10.01M | -11.52M | -10.64M | -10.84M | -11.45M | -9.60M | -12.82M | -16.02M | -18.69M | -15.57M | -13.10M | -13.77M | -13.80M | -15.01M | -17.40M | -17.12M | -24.45M | -18.78M | -26.02M | -21.51M | -36.57M | -11.94M | 3.12M | -8.48M | 2.66M | -12.54M | -18.77M | -24.19M | -30.32M | -20.68M | -516.00K | -64.85M | -43.78M | -36.49M | - | -64.05M | -67.81M | -69.42M | -64.65M | -88.61M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -0.40 | -0.37 | -0.38 | -0.42 | -0.45 | -0.57 | -0.45 | -0.53 | -0.41 | -0.64 | -0.21 | -0.24 | -0.25 | -0.23 | -0.22 | -0.25 | -0.31 | -0.39 | -0.26 | -0.25 | -0.49 | -0.26 | -0.22 | - | -0.38 | -0.39 | -0.38 | -0.29 | -0.40 |
| R&D Expense | 6.74M | 8.26M | - | 7.07M | 6.98M | 5.69M | - | 6.73M | 8.12M | 8.13M | - | 8.23M | 8.74M | 9.69M | - | 11.32M | 9.41M | 10.23M | - | 6.10M | 8.02M | 6.95M | 10.93M | 13.86M | 12.72M | 13.10M | 13.10M | 13.72M | 14.75M | 15.09M | 15.02M | 20.73M | 28.86M | 37.05M | - | 42.86M | 51.08M | 52.36M | - | 66.21M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 1.92M | 1.99M | 4.23M | 17.40M | - | 51.49M | 58.44M | 63.72M | 51.95M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | 4.54M | 5.28M | 5.63M | 6.57M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | 46.95M | 53.16M | 58.10M | 45.38M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 125.61M | 135.54M | 229.88M | 315.39M |
| Operating Income | -13.67M | -12.90M | -27.09M | -38.20M | -43.33M | -61.92M | -59.12M | -85.80M | -62.85M | - | -78.65M | -82.38M | -171.78M | -270.02M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -61.91M | -66.42M | -176.14M | -249.78M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | 7.02M | 11.34M | 13.58M | 11.84M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -71.04M | -80.74M | -193.51M | -265.94M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -14.09M | -13.32M | -28.65M | -39.75M | -44.70M | -63.39M | -59.98M | -86.37M | -155.64M | - | -71.04M | -80.74M | -193.51M | -265.94M |
| Diluted EPS | - | - | - | - | - | - | - | -1.91 | -2.56 | - | -0.97 | -1.02 | -1.22 | -1.42 |
| R&D Expense | 11.54M | 10.52M | 18.88M | 26.61M | 27.07M | 30.88M | 36.91M | 41.09M | 28.69M | 50.08M | 53.46M | 61.05M | 127.64M | 197.10M |
Compounded Sales Growth
| 5 Years: | 0.29% |
| 1 Year: | 0.80% |
Compounded Profit Growth
| 5 Years: | -91.45% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +12.48% |
| 6 Months: | -25.72% |
| 3 Months: | +0.78% |
| 1 Month: | -2.17% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 19.15M | 78.19M | 110.31M | 74.94M | 55.43M | 73.04M | 78.74M | 261.86M | - | 149.29M | 252.06M | 457.94M | 808.06M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | 129.63M | 232.24M | 440.99M | 782.13M |
| Cash & Equivalents | 5.33M | 23.85M | 17.50M | 37.39M | 30.78M | 32.94M | 41.54M | 54.06M | 54.44M | 228.06M | - | 102.30M | 195.81M | 392.10M | 737.06M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | 1.97M | 2.31M | 3.04M | 3.56M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | 21.32M | 26.18M | 32.39M | 30.65M |
| Total Liabilities | - | - | 4.27M | 19.50M | 20.72M | 22.93M | 29.28M | 37.17M | 82.37M | 185.77M | - | 113.91M | 160.93M | 142.59M | 153.75M |
| Current Liabilities | - | - | 3.34M | 5.87M | 5.38M | 8.30M | 13.43M | 9.16M | 12.03M | 26.66M | - | 31.39M | 34.90M | 41.35M | 50.81M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | 54.01M | 74.92M | 68.50M | 71.34M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | 64.28M | 83.39M | 75.78M | 76.97M |
| Total Equity | -32.73M | -46.61M | -59.47M | 58.70M | 89.59M | 52.01M | 26.15M | 35.88M | -3.63M | 76.09M | - | 35.38M | 91.13M | 315.34M | 654.31M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 77.20M | 114.96M | 157.75M | 215.93M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -33.74M | -34.00M | -50.47M | -49.23M | -77.58M | -53.55M | - | -59.60M | -70.23M | -134.68M | -204.88M |
| Investing Cash Flow | - | - | - | -38.57M | 37.07M | 26.95M | -1.89M | -2.24M | -841.00K | - | -3.71M | -6.09M | -1.29M | -11.88M |
| Financing Cash Flow | - | - | - | 65.70M | 585.00K | 32.01M | 68.64M | 75.34M | 228.01M | - | 1.45M | 169.83M | 332.11M | 561.72M |
| Capital Expenditure | -203.00K | -387.00K | -1.26M | -1.78M | -1.92M | -8.25M | -1.89M | -2.24M | -841.00K | - | -3.71M | -6.09M | -1.29M | -12.01M |
| Free Cash Flow | - | - | - | -35.52M | -35.92M | -58.73M | -51.12M | -79.82M | -54.40M | - | -63.32M | -76.32M | -135.97M | -216.89M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | -61.86M | 93.51M | 196.15M | 344.96M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | 91.2% | 91.0% | 91.2% | 87.3% |
| Operating Margin % | - | - | - | - | - | -3,220.1% | -2,970.8% | -2,029.9% | -361.1% | - | -152.7% | -141.0% | -269.6% | -519.8% |
| Net Margin % | - | - | - | - | - | -3,296.2% | -3,014.0% | -2,043.3% | -894.3% | - | -138.0% | -138.1% | -303.7% | -511.9% |
| ROE % | 30.2% | 22.4% | -48.8% | -44.4% | -86.0% | -242.4% | -167.2% | 2,379.4% | -204.5% | - | -200.8% | -88.6% | -61.4% | -40.6% |
| ROCE % | - | -81.6% | -37.5% | -36.4% | -65.0% | -147.4% | -92.5% | -128.6% | -26.7% | - | -66.7% | -37.9% | -41.2% | -35.7% |
Shareholding Pattern
Insiders
0.87%
Institutions
95.67%
Public Float
96.51%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.91% | 32.65M | $294.21M |
| 2 | Deep Track Capital, Lp | 8.99% | 19.69M | $177.37M |
| 3 | Blackrock Inc. | 7.37% | 16.13M | $145.36M |
| 4 | Avoro Capital Advisors LLC | 5.62% | 12.31M | $110.96M |
| 5 | Summer Road LLC | 5.43% | 11.88M | $107.04M |
| 6 | Venrock Adviser, LLC | 4.73% | 10.35M | $93.23M |
| 7 | Vanguard Capital Management LLC | 3.98% | 8.72M | $78.56M |
| 8 | Price (T.Rowe) Associates Inc | 2.69% | 5.90M | $53.13M |
| 9 | Point72 Asset Management, L.P. | 2.53% | 5.53M | $49.87M |
| 10 | State Street Corporation | 2.15% | 4.71M | $42.42M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OCUL
No recent headlines available.